Dr Paul Reynolds

Dr Paul Reynolds
Lecturer and Director of Postgraduate Studies



I gained my PhD in 1997 from the Department of Pathology, University of Bristol, in Keith Brown’s lab. In 1998, I became a postdoctoral fellow in Dr Daniel Haber’s lab at Harvard Medical School/Massachusetts General Hospital Cancer Center, USA and then in 2003 I moved to the University of California, San Francisco in order to work with Dr Thea Tlsty investigating the epigenetic modulation of primary human mammary epithelial cells. I was appointed to a Lectureship at the University of St. Andrews in June 2007.

Why do some patients respond to therapy and some don’t? There is a growing need to personalise therapeutic treatments because human diseases are somewhat unique to the individual patient. Diagnostic assays detecting specific features (biomarkers) of a disease provide a framework to classify diseases according to their underlying molecular defects. In turn, the patient-specific molecular profile guides the clinician’s choice for therapy. Cancer is a remarkably heterogenous disease and the increasing complexity of molecular changes that occur during tumour evolution highlights the importance of identifying events that drive this process. Renal podocytes are essential for the normal filtration function of our kidneys. With the increasing use of molecularly targeted cancer therapies, the toxic side-effects of targeted agents are increasingly being recognized and the renal safety of these drugs is becoming an important health issue.

The Reynolds lab is interested in identifying those molecular changes which drive disease with particular emphasis on 1) cancer resistance mechanisms to therapeutic drugs and 2) the mechanobiology of kidney podocytes in health and disease. We are employing biochemistry, molecular biology and cell biology approaches to investigate the nature and context of these factors and how they impact upon human health.

School Roles:

  • Director of Postgraduate Studies (DoPG)

  • School Advisor on Biological Safety

  • Deputy Module Controller MD3002

  • Tissue culture room Curator

data source: symbiosis

Research Overview from research@st-andrews

Systems Pathology and Cancer

Why do some patients respond to therapy and some don’t? There is a growing need to personalise therapeutic treatments because human diseases are somewhat unique to the individual patient. Diagnostic assays detecting specific features (biomarkers) of a disease provide a framework to classify diseases according to their underlying molecular defects. In turn, the patient-specific molecular profile guides the clinician’s choice for therapy. Cancer is a remarkably heterogenous disease and the increasing complexity of molecular changes that occur during tumour evolution highlights the importance of identifying events that drive this process. Renal podocytes are essential for the normal filtration function of our kidneys.  With the increasing use of molecularly targeted cancer therapies, the toxic side-effects of targeted agents are increasingly being recognized and the renal safety of these drugs is becoming an important health issue.

The Reynolds lab is interested in identifying those molecular changes which drive disease with particular emphasis on 1) cancer resistance mechanisms to therapeutic drugs and 2) the mechanobiology of kidney podocytes in health and disease. We are employing biochemistry, molecular biology and cell biology approaches to investigate the nature and context of these factors and how they impact upon human health.

 


source: research@st-andrews
Recent publications listed in research@st-andrews
Tilston-Lunel, AM, Haley, K, Schlecht, N, Wang, Y, Chatterton, ALD, Moleirinho, SL, Watson, A, Hundal, H, Prystowsky, M, Gunn-Moore, FJ & Reynolds, PA 2016, 'Crumbs 3b promotes tight junctions in an ezrin-dependent manner in mammalian cells' Journal of Molecular Cell Biology, vol. 8, no. 5, pp. 439-455. DOI: 10.1093/jmcb/MJW020
Caie, PD, Schuur, K, Oniscu, A, Mullen, P, Reynolds, PA & Harrison, DJ 2013, 'Human tissue in systems medicine' FEBS Journal, vol. 280, no. 23, pp. 5949–5956. DOI: 10.1111/febs.12550
Moleirinho, S, Patrick, C, Tilston-Lunel, AM, Higginson, JR, Angus, L, Antkowiak, M, Barnett, S, Prystowsky, M, Reynolds, PA & Gunn-Moore, FJ 2013, 'Willin, an upstream component of the Hippo signaling pathway, orchestrates mammalian peripheral nerve fibroblasts' PLoS One, vol. 8, no. 4, e60028. DOI: 10.1371/journal.pone.0060028
Moleirinho, S, Chang, N, Sims, A, Tilston-Lunel, AM, Angus, L, Steele, A, Boswell, V, Barnett, S, Ormandy, C, Faratian, D, Gunn-Moore, FJ & Reynolds, PA 2013, 'KIBRA Exhibits MST-independent Functional Regulation of the Hippo Signaling Pathway in Mammals' Oncogene, vol. 32, no. 14, pp. 1821-1830. DOI: 10.1038/onc.2012.196
Moleirinho, S, Tilston-Lunel, AM, Angus, L, Gunn-Moore, FJ & Reynolds, PA 2013, 'The Expanding Family of FERM Proteins.' Biochemical Journal, vol. 452 , no. 2, pp. 183-193 . DOI: 10.1042/BJ20121642
Giricz, O, Reynolds, PA, Ramnauth, A, Liu, C, Wang, T, Stead, L, Childs, G, Rohan, T, Shapiro, N, Fineberg, S, Kenny, P & Loudig, O 2012, 'Hsa-miR-375 Is Differentially Expressed During Breast Lobular Neoplasia And Promotes Loss Of Mammary Acinar Polarity' Journal of Pathology, vol. 226, no. 1, pp. 108-119. DOI: 10.1002/path.2978
Schlecht, NF, Brandwein-Gensler , M, Smith , RV, Kawachi, N, Broughel, D, Lin, J, Keller , CE, Reynolds, PA, Gunn-Moore, FJ, Harris, T, Childs, G, Belbin, TY & Prystowsky, MB 2012, 'Cytoplasmic Ezrin and Moesin Correlate with Poor Survival in Head and Neck Squamous Cell Carcinoma' Head and Neck Pathology, vol. 6, no. 2, pp. 232-43. DOI: 10.1007/s12105-011-0328-1
Bean, GR, Bryson, AD, Pilie, PD, Goldenberg, V, Baker, JC, Ibarra, C, Brander, DMU, Paisie, C, Case, NR, Gauthier, M, Reynolds, PA, Dietz, E, Ostrander, J, Scott, V, Wilke, LG, Yee, L, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Tlsty, TD & Seewaldt, VL 2007, 'Morphologically Normal-Appearing Mammary Epithelial Cells Obtained from High-Risk Women Exhibit Methylation Silencing of INK4a/ARF.' Clinical Cancer Research, vol. 13, pp. 6834-6841. DOI: 10.1158/1078-0432.CCR-07-0407
Reynolds, PA, Sigaroudinia, M, Zardo, G, Wilson, MB, Benton, G, Miller, C, Hong, C, Fridlyand, J, Costello, JF & Tlsty, TD 2006, 'Tumour Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells' Journal of Biological Chemistry, vol. 281, no. 34, pp. 24790-24802. DOI: 10.1074/jbc.M604175200
Reynolds, PA, Smolen, GA, Palmer, RE, Sgroi, D, Yajnik, V, Gerald, WL & Haber, DA 2003, 'Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein' Genes & Development, vol. 17, no. 17, pp. 2094-2107. DOI: 10.1101/gad.1110703
Yajnik, V, Paulding, C, Sordella, R, McClatchey, AI, Saito, M, Wahrer, DCR, Reynolds, PA, Bell, DW, Lake, R, van den Heuvel, S, Settleman, J & Haber, DA 2003, 'DOCK4, a GTPase Activator, Is Disrupted during Tumourigenesis.' Cell, vol. 112, no. 5, pp. 673-684. DOI: 10.1016/S0092-8674(03)00155-7
Vernon, EG, Malik, K, Reynolds, PA, Powlesland, R, Dallosso, AR, Jackson, S, Henthorn, K, Green, ED & Brown, KW 2003, 'The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour' Oncogene, vol. 22, no. 9, pp. 1371-1380. DOI: 10.1038/sj.onc.1206332
Palmer, R, Lee, S, Wong, J, Reynolds, PA, Zhang, H, Truong, V, Oliner, J, Gerald, W & Haber, D 2002, 'Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis' Cancer Cell, vol. 2, no. 6, pp. 497-505. DOI: 10.1016/S1535-6108(02)00205-2
Wong, JC, Lee, SB, Bell, MD, Reynolds, PA, Fiore, E, Stamenkovic, I, Truong, V, Oliner, JD, Gerald, WG & Haber, DA 2002, 'Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product' Oncogene, vol. 21, no. 13, pp. 2009-2019. DOI: 10.1038/sj.onc.1205262
Powlesland, R, Charles, AK, Malik, KTA, Reynolds, PA, Pires, S, Boavida, M & Brown, KW 2000, 'Loss of heterozygosity at 7p in Wilms' tumour development' British Journal of Cancer, vol. 82, no. 2, pp. 323-329. DOI: 10.1054/bjoc.1999.0922